Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
Become a Member | Sign in
Home>News>This Article

Harris Williams & Co. Advises Caprion in its Sale to CGP

Published: Tuesday, July 31, 2012
Last Updated: Monday, July 30, 2012
Bookmark and Share
Caprion provides integrated proteomic biomarker solutions and immune monitoring services.

Harris Williams & Co. has announced the sale of Caprion Proteomics, Inc. (Caprion), the leading provider of integrated proteomic biomarker and target identification solutions and immune monitoring services, to Chicago Growth Partners (CGP).

Caprion was a portfolio company of Great Point Partners (GPP). Harris Williams & Co. acted as an advisor to Caprion.

The transaction closed on July 19, 2012 and was led by James Clark, Turner Bredrup, Geoff Smith, Whit Knier and Paul Hepper from the firm's Healthcare & Life Sciences (HCLS) Group.

"Caprion has established itself as the market leader in providing outsourced proteomic biomarker discovery and immune monitoring services for its growing list of blue-chip pharmaceutical and biotechnology clients. Caprion is well positioned as the pharmaceutical industry continues to outsource critical elements of the drug development process to maximize returns on its research and development spend," said James Clark, a managing director in Harris Williams & Co.'s HCLS Group.

Caprion is the leading provider of proteomics services to many of the largest and most successful pharmaceutical and biotechnology companies, as well as several government research institutions.

Caprion's key services include: (i) biomarker discovery, (ii) biomarker validation, (iii) drug target discovery, (iv) advanced immune monitoring services, and (v) clinical diagnostic product development.

The company's proprietary CellCarta technology is the leading biomarker discovery and validation platform in the growing field of proteomics, and has overcome technical limitations of earlier proteomics technologies by developing and effectively putting into industrial practice a powerful proteomics engine for highly multiplexed, unbiased measurement of protein abundance differences across large sample sets.

GPP, based in Greenwich, CT, is a leading healthcare investment firm with approximately $400 million of equity capital under management. The firm manages capital in public and private equity funds.

GPP has provided growth equity, growth recapitalization and management buyout financing to more than 100 healthcare companies.

The private equity fund invests in profitable companies across all sectors of the healthcare industry including behavioral health, biologics manufacturing, healthcare services, hospital outsourcing, information technology, life sciences, media and reagents, medical devices, rehabilitation, specialty pharmaceuticals and workers' compensation.

For over 25 years and across more than 100 growth companies, the principals of CGP have partnered with quality management teams to help facilitate their growth objectives.

CGP executes its growth-focused investment strategy across four industries: education, tech-enabled services, healthcare and industrial growth. CGP currently manages $1.2 billion of committed capital and has offices in Chicago and La Jolla.

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,200+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Structure of Primary Cannabinoid Receptor is Revealed
The findings provide key insights into how natural and synthetic cannabinoids including tetrahydrocannabinol —a primary chemical in marijuana—bind at the CB1 receptor to produce their effects.
Targeting Cannabinoid CB2 Receptors in the CNS
With endogenous cannabinoids considered as a potential target to combat CNS diseases, this article examines the role of CB2R could play in fighting some disorders.
3D-Printing in Science: Conference Co-Staged with LABVOLUTION
LABVOLUTION 2017 will have an added highlight of a simultaneous conference, "3D-Printing in Science".
Charles River Acquires Agilux
Enhances Charles River’s early-stage capabilities in bioanalytical services.
Designing Drugs with a Whole New Toolbox
Researchers develop methods to design small, targeted proteins with shapes not found in nature.
Small Molecules Lead to a Big Change in Reaction Outcomes
Scientists have changed the behaviour of a group of molecules involved in carbon-oxygen bond synthesis.
Targeting Fat to Treat Cancer
Researchers develop novel cancer treatment that halts fat synthesis in cells, stunting tumors.
Hyperstable Peptides for 'On-Demand' Drugs
These small molecules can fold into different conformations that could allow for greater flexibility in precision drug design
Drug Leads Identified to Combat Heart Disease
Using three supercomputers, researchers surveyed protein structures through accelerated molecular dynamics.
Accelerating the Path to Molecules for Medicine
Researchers convert carbon-hydrogen bonds into nitriles - converting organic molecules into components of medicines.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,200+ scientific videos